Notice Regarding the Signing of a Joint Research Agreement with Nagoya University

—Development of Novel Therapies for Neurological Disorders Using iPS Cell Technology—

November 18, 2026

REPROCELL Inc. (the “Company”) announces that it has entered into a joint research agreement with The Tokai National Higher Education and Research System to conduct collaborative research (the “Joint Research”) with the Center for Maternal-Neonatal Care at Nagoya University Hospital. The purpose of the Joint Research is to develop novel therapies for neurological disorders using human induced pluripotent stem (iPS) cells or cells derived from them (collectively, “iPS cell technology”).

The Joint Research will combine the technologies and expertise in iPS cells that the Company has developed to date with those of the Center for Maternal-Neonatal Care at Nagoya University Hospital, with the aim of developing new therapies for neurological disorders using iPS cell technology.

Through the Joint Research, the Company will advance research and development toward the medical application of iPS cell technology.

At present, the impact of this matter on the Company’s consolidated financial results for the current fiscal year is expected to be minor. Should any matters requiring disclosure arise in the future, the Company will promptly disclose them.